Evidence map›Paper›PMID 39034641›Full record

ReviewEuropean journal of neurology2024

Behavioral therapy in migraine: Expanding the therapeutic arsenal.

Ane Mínguez-Olaondo, Patricia Alves Días, Estibaliz López de Munáin, Vesselina Grozeva, Carmen Laspra-Solís, Inés Martín Villalba, Valvanuz García-Martín, Marta Vila-Pueyo, Myriam Barandiarán, Ramon J Zabalza and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Non-pharmacological approaches for migraine management: a mini-review.Frontiers in pain research (Lausanne, Switzerland) · 2026
    Review
  3. Real-world application of Short Term Psychodynamic Psychotherapy (STPP) as chronic migraine preventive therapy: Profiling responders and predictive factors.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Observational
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ane Mínguez-OlaondoNeurology Department, Hospital Universitario Donostia-Osakidetza , Neuroscience Area, Biogipuzkoa Health Institute, Donostia, Spain.
Patricia Alves DíasNeurology Department, Hospital Universitario Donostia-Osakidetza , Neuroscience Area, Biogipuzkoa Health Institute, Donostia, Spain.
Estibaliz López de MunáinAthenea Neuroclinics, Donostia, Spain.
Vesselina GrozevaNeurology Practice, Sofia, Bulgaria.
Carmen Laspra-SolísDepartment of Psychiatry and Clinical Psychology, University Clinic of Navarra, Madrid, Spain.
Inés Martín VillalbaHospital Clínic i Provincial de Barcelona, Department of Neurology, Spain.
Valvanuz García-MartínNeurology Department, Hospital Universitario Donostia-Osakidetza , Neuroscience Area, Biogipuzkoa Health Institute, Donostia, Spain.ORCID 0009-0006-7568-9967
Marta Vila-PueyoHeadache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Myriam BarandiaránNeurology Department, Hospital Universitario Donostia-Osakidetza , Neuroscience Area, Biogipuzkoa Health Institute, Donostia, Spain.
Ramon J ZabalzaNeurology Department, Hospital Universitario Donostia-Osakidetza , Neuroscience Area, Biogipuzkoa Health Institute, Donostia, Spain.
Ana BengoetxeaAthenea Neuroclinics, Donostia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe US Headache Consortium developed evidence-based guidelines for the treatment of migraine and found grade A evidence in support of behavior therapy (BT). Understanding the mechanisms of BT may improve the management of migraine and reduce its burden.

methodsWe performed a narrative review to define the current evidence of BT and determine its usefulness in migraine management.

resultsThe information was obtained from 116 publications, with 56 of them retrieved through direct searches in PubMed (2011-2020) and the remainder selected by the authors to complete the content. BT might reduce migraine impact by decreasing the sympathetic nervous system's response to stress and increasing pain tolerance. Acting in headache-related surroundings can be improved, together with headache duration and self-efficacy. Applications such as mobile health and electronic health applications can help to carry out healthier lifestyle patterns. Regarding medication overuse, BT seems to be a good choice, with similar results to pharmacological prophylaxis. Advantages of using BT are the lack of adverse effects and the unrestricted use in children, where BT is postulated to be even more effective than the standardized pharmacopeia.

conclusionsBT is an interesting tool that can be used as an add-on therapy in migraine. Through BT, the autonomy and empowerment of migraine patients is enhanced. BT may not cure migraine, but it could help to reduce pain severity perception, disability, and migraine impact, adding an emotive and cognitive approach to the perceptive role of pharmacopeia. Thus, a better approach in migraine, implementing specific therapeutic management, can improve migraine control.

Indexed as

Behavior TherapyMigraine DisordersHumansbehavioraldisabilitymanagementmigrainetherapy

Identifiers

PMID39034641
PMCPMC11555010

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.